{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:32Z","timestamp":1791235412275,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/jnci\/dju033","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T23:25:05Z","timestamp":1394839505000},"source":"Crossref","is-referenced-by-count":63,"title":["Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib"],"prefix":"10.1093","volume":"106","author":[{"given":"Timothy J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Box","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Spinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne A.","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,14]]},"reference":[{"issue":"20","key":"key\n\t\t\t\t20170520222743_CIT0001","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"12","key":"key\n\t\t\t\t20170520222743_CIT0002","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-10-3120","article-title":"Characterization of bone metastases from rapid autopsies of prostate cancer patients","volume":"17","author":"Mehra","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"16","key":"key\n\t\t\t\t20170520222743_CIT0003","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170520222743_CIT0004","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","article-title":"New molecular targets in bone metastases","volume":"36","author":"Santini","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"key\n\t\t\t\t20170520222743_CIT0005","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"key\n\t\t\t\t20170520222743_CIT0006","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2010.34.4994","article-title":"Emerging therapies to prevent skeletal morbidity in men with prostate cancer","volume":"29","author":"Saylor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170520222743_CIT0007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrclinonc.2011.67","article-title":"Bone metastasis in prostate cancer: emerging therapeutic strategies","volume":"8","author":"Sturge","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"key\n\t\t\t\t20170520222743_CIT0008","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/pr0500915","article-title":"Imaging biomarkers in drug development: an overview of opportunities and open issues","volume":"4","author":"Chandra","year":"2005","journal-title":"J Proteome Res"},{"issue":"10","key":"key\n\t\t\t\t20170520222743_CIT0009","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170520222743_CIT0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"key\n\t\t\t\t20170520222743_CIT0011","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"key\n\t\t\t\t20170520222743_CIT0012","first-page":"386","article-title":"Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma","volume":"147","author":"Humphrey","year":"1995","journal-title":"Am J Pathol"},{"issue":"6","key":"key\n\t\t\t\t20170520222743_CIT0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","article-title":"High expression of the Met receptor in prostate cancer metastasis to bone","volume":"60","author":"Knudsen","year":"2002","journal-title":"Urology"},{"issue":"4","key":"key\n\t\t\t\t20170520222743_CIT0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3816\/CGC.2006.n.006","article-title":"Prognostic significance of plasma scatter factor\/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005\/9480","volume":"4","author":"Humphrey","year":"2006","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"key\n\t\t\t\t20170520222743_CIT0015","first-page":"2533","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study","volume":"61","author":"Bok","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"key\n\t\t\t\t20170520222743_CIT0016","first-page":"1932","article-title":"Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480","volume":"7","author":"George","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20170520222743_CIT0017","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase ii randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"key\n\t\t\t\t20170520222743_CIT0018","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"key\n\t\t\t\t20170520222743_CIT0019","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1593\/neo.12308","article-title":"The IGR-CaP1 xenograft model recapitulates mixed osteolytic\/blastic bone lesions observed in metastatic prostate cancer","volume":"14","author":"Al Nakouzi","year":"2012","journal-title":"Neoplasia"},{"issue":"4","key":"key\n\t\t\t\t20170520222743_CIT0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006106209527","article-title":"Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone","volume":"17","author":"Lange","year":"1998","journal-title":"Cancer Metastasis Rev"},{"issue":"5748","key":"key\n\t\t\t\t20170520222743_CIT0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"2","key":"key\n\t\t\t\t20170520222743_CIT0022","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1593\/neo.81328","article-title":"Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations","volume":"11","author":"Padhani","year":"2009","journal-title":"Neoplasia"},{"issue":"6","key":"key\n\t\t\t\t20170520222743_CIT0023","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1593\/tlo.12298","article-title":"Multimodality imaging of tumor and bone response in a mouse model of bony metastasis","volume":"5","author":"Hoff","year":"2012","journal-title":"Transl Oncol"},{"issue":"12","key":"key\n\t\t\t\t20170520222743_CIT0024","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1593\/neo.07954","article-title":"A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone","volume":"9","author":"Lee","year":"2007","journal-title":"Neoplasia"},{"issue":"10","key":"key\n\t\t\t\t20170520222743_CIT0025","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00330-011-2173-8","article-title":"Assessing response in bone metastases in prostate cancer with diffusion weighted MRI","volume":"21","author":"Messiou","year":"2011","journal-title":"Eur Radiol"},{"issue":"8","key":"key\n\t\t\t\t20170520222743_CIT0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00330-011-2116-4","article-title":"Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility","volume":"21","author":"Messiou","year":"2011","journal-title":"Eur Radiol"},{"key":"key\n\t\t\t\t20170520222743_CIT0027","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1102\/1470-7330.2011.9034","article-title":"Bony metastases: assessing response to therapy with whole-body diffusion MRI","volume":"11","author":"Padhani","year":"2011","journal-title":"Cancer Imaging"},{"issue":"1","key":"key\n\t\t\t\t20170520222743_CIT0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.semnuclmed.2011.07.005","article-title":"The bone scan","volume":"42","author":"Brenner","year":"2012","journal-title":"Semin Nucl Med"},{"issue":"3","key":"key\n\t\t\t\t20170520222743_CIT0029","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1148\/radiology.176.3.2202009","article-title":"Clinical radionuclide bone imaging","volume":"176","author":"Holder","year":"1990","journal-title":"Radiology"},{"issue":"4","key":"key\n\t\t\t\t20170520222743_CIT0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1148\/radiographics.13.4.8356264","article-title":"Extraosseous Tc-99m MDP uptake: a pathophysiologic approach","volume":"13","author":"Peller","year":"1993","journal-title":"Radiographics"},{"issue":"2","key":"key\n\t\t\t\t20170520222743_CIT0031","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jor.1100040206","article-title":"Localization of technetium-99m methylene diphosphonate in bone using microautoradiography","volume":"4","author":"Einhorn","year":"1986","journal-title":"J Orthop Res"},{"issue":"2","key":"key\n\t\t\t\t20170520222743_CIT0032","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1464-410X.1997.00237.x","article-title":"Serum pyridinoline crosslinks as markers of tumor-induced bone resorption","volume":"80","author":"Nemoto","year":"1997","journal-title":"Br J Urol"},{"issue":"5","key":"key\n\t\t\t\t20170520222743_CIT0033","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bone.2006.04.033","article-title":"Osteoclasts play a part in pain due to the inflammation adjacent to bone","volume":"39","author":"Nagae","year":"2006","journal-title":"Bone"},{"issue":"5","key":"key\n\t\t\t\t20170520222743_CIT0034","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"key\n\t\t\t\t20170520222743_CIT0035","doi-asserted-by":"crossref","first-page":"986v989","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Ann Oncol"},{"issue":"25","key":"key\n\t\t\t\t20170520222743_CIT0036","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","article-title":"Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"key\n\t\t\t\t20170520222743_CIT0037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrurol.2009.130","article-title":"Prostate cancer: PSA as an intermediate end point in clinical trials","volume":"6","author":"Attard","year":"2009","journal-title":"Nat Rev Urol"},{"issue":"9","key":"key\n\t\t\t\t20170520222743_CIT0038","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/106\/4\/dju033\/17313400\/dju033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:36:52Z","timestamp":1565257012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/dju033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,14]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,3,14]]},"published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dju033","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,14]]}}}